axSpA, and –20 for patients with PsA; figure 1). Quality of life improved by –5 for patients with axSpA and PsA, and by –7 for patients with RA.

Conclusions: This interim analysis shows that golimumab treatment is effective in improving work productivity, daily activities as well as quality of life already within the first 3 months of treatment in RA, axSpA and PsA patients.


FRIO109

DRUG IMMUNOGENICITY AND THE DEVELOPMENT OF PARADOXICAL ADVERSE EVENTS WITH BIOLOGIC THERAPIES

C. Ancuta1, C. Pomirleanu1, R. Paiu1, G. Strugaru1, L. Petran1, E. Ancuta2, A. Chiriac2, C. Romanescu2. 1Clinical Rehabilitation Hospital; 2University of Medicine and Pharmacy Grigore T Popa Iasi; Romania

Background: Defined as de novo or exacerbation of pathologies that usually responds to biologic agents, paradoxical reactions encompass for a wide spectrum of manifestations (cutaneous, intestinal, ocular) reported during biological therapy (TNF and non-TNF medications) regardless of the underlying rheumatic or non-rheumatic disorder.

Objectives: To assess drug levels (DL) and anti-drug antibodies (ADA) in patients with paradoxical reactions (de novo or exacerbation of psoriasis, uveitis, Crohn's disease) induced by biological drugs (bDMARS) in Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA).

Methods: We performed a retrospective observational study in cohorts of consecutive RA (267), PsA (65) and AS (145) undergoing TNF (i-TNF) or non-TNF biologics according to the local recommendations for initiation and monitoring, attended by a single academic rheumatology department. All patients were assessed at every 24 weeks months for disease activity and outcome by country by additionally including an interaction term between treatment, seropositivity and country. Since we found no effect modification, we took out the interaction term. Effectiveness was analysed using DAS28 remission and low disease activity (LDA) at 1 year, corrected for attrition using Lunedex.

Results: Using data from 39 266 treatment-courses, in crude analyses, seropositivity and country. Since we found no effect modification, we took out the interaction term. Effectiveness was analysed using DAS28 remission and low disease activity (LDA) at 1 year, corrected for attrition using Lunedex.